-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Cormedix, Lowers Price Target to $12

Benzinga·11/02/2026 17:57:15
Diffusion vocale
Needham analyst Serge Belanger maintains Cormedix (NASDAQ:CRMD) with a Buy and lowers the price target from $15 to $12.